NYSE:VNRX VolitionRx (VNRX) Stock Price, News & Analysis → Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad) Free VNRX Stock Alerts $0.89 +0.01 (+1.14%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.85▼$0.9150-Day Range$0.60▼$1.0652-Week Range$0.55▼$2.09Volume106,874 shsAverage Volume320,236 shsMarket Capitalization$73.12 millionP/E RatioN/ADividend YieldN/APrice Target$2.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Get VolitionRx alerts: Email Address Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About VolitionRx Stock (NYSE:VNRX)VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.Read More VNRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VNRX Stock News HeadlinesMay 4, 2024 | americanbankingnews.comVolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.comApril 26, 2024 | americanbankingnews.comVolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.comMay 4, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 8, 2024 | msn.comVNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method ...April 8, 2024 | finance.yahoo.comVNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method (Capture -PCR) 2) Nu.Q NET for SepsisMarch 25, 2024 | msn.comVNRX Stock Earnings: VolitionRX Meets EPS, Misses Revenue for Q4 2023March 25, 2024 | prnewswire.comVolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business UpdateMarch 22, 2024 | benzinga.comEarnings Outlook For VolitionRXMay 4, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).March 21, 2024 | prnewswire.comVolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business UpdateMarch 21, 2024 | finanznachrichten.deVolitionRx Limited: Volition appoints Dr Andrew Retter as Chief Medical OfficerMarch 19, 2024 | markets.businessinsider.comVolitionRx Names Andrew Retter Chief Medical OfficerMarch 19, 2024 | finance.yahoo.comVolition appoints Dr Andrew Retter as Chief Medical OfficerMarch 19, 2024 | money.usnews.comVolitionRX LtdFebruary 22, 2024 | benzinga.comVolitionRX Stock (AMEX:VNRX), Short Interest ReportJanuary 2, 2024 | msn.comVolitionRx stock soars after company discloses $13M in milestone paymentsJanuary 2, 2024 | realmoney.thestreet.comVolitionRx milestone payment 'important step forward,' says EF HuttonNovember 17, 2023 | finance.yahoo.comVolition Presents at the 5th Annual Congress of the International Liquid Biopsy SocietyNovember 8, 2023 | proactiveinvestors.comVolitionRx to host Q3 earnings call on November 15October 28, 2023 | markets.businessinsider.comVolitionRX’s Innovative Cancer Detection Platform: A Promising Investment – An Analyst’s PerspectiveSee More Headlines Receive VNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today5/03/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNYSE:VNRX CUSIPN/A CIK93314 WebN/A Phone646-650-1351Fax65 32 8172 5651Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$2.50 High Stock Price Target$2.50 Low Stock Price Target$2.50 Potential Upside/Downside+180.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,320,000.00 Net Margins-4,557.29% Pretax Margin-4,603.48% Return on EquityN/A Return on Assets-154.24% Debt Debt-to-Equity RatioN/A Current Ratio0.69 Quick Ratio0.69 Sales & Book Value Annual Sales$770,000.00 Price / Sales94.96 Cash FlowN/A Price / Cash FlowN/A Book Value($0.11) per share Price / Book-8.10Miscellaneous Outstanding Shares82,070,000Free Float69,430,000Market Cap$73.12 million OptionableOptionable Beta1.26 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Martin Charles Faulkes Ph.D. (Age 80)Executive Chairman Comp: $239.51kMr. Cameron Reynolds MBA (Age 53)Founder, CEO, President & Director Comp: $572.43kDr. Gaetan Michel Ph.D. (Age 50)Chief Operating Officer Comp: $518.15kDr. Salvatore Thomas Butera DVM (Age 72)Chief Executive Officer of Volition Veterinary Diagnostics Development LLC Comp: $477.25kMr. Terig Hughes (Age 53)CFO & Treasurer Comp: $338.74kDr. Jacob Vincent Micallef MBA (Age 68)Ph.D., Chief Scientific Officer Comp: $571.55kMr. Nicholas Plummer (Age 53)Group General Counsel Ms. Louise Batchelor Day (Age 52)Group Chief Marketing & Communications Officer Mr. Thomas BygottSales & Marketing DirectorMr. Gael Forterre M.B.A. (Age 42)Chief Commercial Officer More ExecutivesKey CompetitorsAlpha TeknovaNASDAQ:TKNOARCA biopharmaNASDAQ:ABIOAspira Women's HealthNASDAQ:AWHImmuCellNASDAQ:ICCCOncoCyteNASDAQ:OCXView All CompetitorsInsidersCorp Ltd EightSold 20,000 sharesTotal: $18,000.00 ($0.90/share)Salvatore Thomas ButeraBought 10,000 shares on 12/18/2023Total: $8,300.00 ($0.83/share)Corp Ltd EightSold 20,000 sharesTotal: $15,000.00 ($0.75/share)Salvatore Thomas ButeraBought 10,000 shares on 12/15/2023Total: $7,700.00 ($0.77/share)Rodney Gerard RootsaertBought 10,000 shares on 12/13/2023Total: $6,000.00 ($0.60/share)View All Insider Transactions VNRX Stock Analysis - Frequently Asked Questions Should I buy or sell VolitionRx stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" VNRX shares. View VNRX analyst ratings or view top-rated stocks. What is VolitionRx's stock price target for 2024? 1 Wall Street analysts have issued twelve-month price targets for VolitionRx's stock. Their VNRX share price targets range from $2.50 to $2.50. On average, they anticipate the company's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 180.6% from the stock's current price. View analysts price targets for VNRX or view top-rated stocks among Wall Street analysts. How have VNRX shares performed in 2024? VolitionRx's stock was trading at $0.7170 at the beginning of the year. Since then, VNRX shares have increased by 24.3% and is now trading at $0.8909. View the best growth stocks for 2024 here. When is VolitionRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our VNRX earnings forecast. How were VolitionRx's earnings last quarter? VolitionRx Limited (NYSE:VNRX) issued its earnings results on Monday, March, 25th. The company reported ($0.11) EPS for the quarter. The business had revenue of $0.24 million for the quarter, compared to analysts' expectations of $0.50 million. How do I buy shares of VolitionRx? Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:VNRX) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.